Thank you.
This post is a concise and precise compendium of all of the cogent trials research on Anavex 2-73, first in rodents, then humans.
It appears that those who have elected to take profits by selling AVXL shares in recent days are utterly unaware or unable to understand the profound biological significance of these studies.
As I’ve stated several times before (as a biologist who comprehends the essential and utterly unique biochemistry of 2-73 and its cellular targets, the endoplasmic reticula and mitochondria), the existing studies of 2-73 show conclusively that a) it improves by significant degrees cognition in Alzheimer’s patients, in interestingly short periods (weeks, not months or years), and just as importantly (even more so, to get FDA approval), b) 2-73 simply evokes no side effects of any consequence whatsoever at efficacious dosages.
Now it is clear the majority of recent traders in AVXL are chartists or short-term day traders, playing short-term share price trends for moderate profits (compared to those Anavex will yield in a year or more). I am not a day-trader and have no expertise or interest in this investment approach. I wish those playing those games the best.
My small Anavex position will be held for at least a year. I won’t be selling a single share until Anavex (or its purchaser) attains Big Pharma status, with the literally billions of dollars of annual revenues 2-73 and the other drugs in the pipeline will generate.
Most of those buying and selling today are playing off their knowledge of price trends and charts. More power to them. Personally, I am guided by the profound science of Anavex. It will take longer for me to benefit, but I will be selling AVXL shares valued in three or four digits. The science and sociology (compassionate relief for millions of neurodegenerative disease sufferers) of 2-73 will, in the end, prevail.
Just as antibiotics changed medicine in the ‘40s and ‘50s, Anavex will revolutionize 21st-century medicine in the next decade.
